These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25534140)

  • 41. Interdependence of hepatic lipid and glucose metabolism: novel pharmacological targets for diabetes.
    Lind P
    Curr Opin Investig Drugs; 2004 Apr; 5(4):395-401. PubMed ID: 15134280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A new therapeutic option for diabetes patients].
    Mihălţan F; Ulmeanu R; Râşnoveanu R
    Pneumologia; 2005; 54(4):181-5. PubMed ID: 17069221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advancing therapeutic discovery through phenotypic screening of the extracellular proteome using hydrodynamic intravascular injection.
    Baribault H; Majeti JZ; Ge H; Wang J; Xiong Y; Gardner J; Yang L; Gupte J; Gong Y; Pan Z; Cutler G; Kassner P; Tu H; Shan B; Wu X; Li Y
    Expert Opin Ther Targets; 2014 Nov; 18(11):1253-64. PubMed ID: 25287216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease.
    Henry RR
    Curr Med Res Opin; 2008 Aug; 24(8):2189-202. PubMed ID: 18573228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
    Yki-Järvinen H
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
    Vudattu NK; Herold KC
    Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discontinued drug therapies to treat diabetes in 2014.
    Colca JR
    Expert Opin Investig Drugs; 2015; 24(9):1241-5. PubMed ID: 26083770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel directions for diabetes mellitus drug discovery.
    Maiese K; Chong ZZ; Shang YC; Wang S
    Expert Opin Drug Discov; 2013 Jan; 8(1):35-48. PubMed ID: 23092114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetics of drug response in type 2 diabetes.
    Tkáč I
    Curr Diab Rep; 2015 Jul; 15(7):43. PubMed ID: 25975599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of QSAR and Virtual Screening Studies in Type 2 Diabetes Drug Discovery.
    Pantaleao SQ; Fujii DGV; Maltarollo VG; da C Silva D; Trossini GHG; Weber KC; Scott LPB; Honorio KM
    Med Chem; 2017; 13(8):706-720. PubMed ID: 28530546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mining the Genome for Therapeutic Targets.
    Florez JC
    Diabetes; 2017 Jul; 66(7):1770-1778. PubMed ID: 28603140
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene expression signature: a powerful approach for drug discovery in diabetes.
    Sithara S; Crowley TM; Walder K; Aston-Mourney K
    J Endocrinol; 2017 Feb; 232(2):R131-R139. PubMed ID: 27927696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repurposing Drugs to Target the Diabetes Epidemic.
    Turner N; Zeng XY; Osborne B; Rogers S; Ye JM
    Trends Pharmacol Sci; 2016 May; 37(5):379-389. PubMed ID: 26900045
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug Discovery and Development of Type 2 Diabetes Mellitus: Modern-Integrative Medicinal Approach.
    Ghosh D; Parida P
    Curr Drug Discov Technol; 2016; 13(2):60-7. PubMed ID: 27074851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CE: Type 2 Diabetes: A Pharmacologic Update.
    Keresztes P; Peacock-Johnson A
    Am J Nurs; 2019 Mar; 119(3):32-40. PubMed ID: 30741763
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Vitamin D, obesity, and diabetes:new technology toward drug development against metabolic diseases].
    Miyata Y; Shimomura I
    Clin Calcium; 2016 Mar; 26(3):385-91. PubMed ID: 26923975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Beyond drug discovery: Exploring the physiological and methodological dimensions of zebrafish in diabetes research.
    Roohi TF; Faizan S; Shaikh MF; Krishna KL; Mehdi S; Kinattingal N; Arulsamy A
    Exp Physiol; 2024 Jun; 109(6):847-872. PubMed ID: 38279951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.